Login / Signup

Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective.

Thomas P LodiseMauricio RodriguezSurya ChitraKelly WrightNimish Patel
Published in: Antibiotics (Basel, Switzerland) (2021)
The findings of this simulated model suggest that prioritizing the use of omadacycline over current CABP treatments in hospitalized CABP with a DRS ≥ 6 may potentially reduce attributable HCA-CDI costs. The findings are not unique to omadacycline and could be applied to any antibiotic that confers a lower risk of HCA-CDI relative to current CABP inpatient treatments.
Keyphrases
  • healthcare
  • mental health
  • acute care
  • human health
  • combination therapy
  • childhood cancer
  • replacement therapy